4.3 Review

The interface of depression and obesity

Journal

OBESITY RESEARCH & CLINICAL PRACTICE
Volume 11, Issue 1, Pages 1-10

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.orcp.2016.07.003

Keywords

Obesity; Depression; Body weight; Body mass index; Antidepressant

Funding

  1. Faculty of Science and Ramathibodi Hospital, Mahidol University
  2. Faculty of Science and Ramathibodi Hospital, Mahidol University

Ask authors/readers for more resources

Depression and obesity are both highly prevalent and are leading public health problems. These foregoing disorders independently have great impact on morbidity and mortality affecting patients' health and well-being as well as on the socioeconomic aspect of functional impairment and healthcare expenditure. Results from epidemiological studies, clinical trials and recent meta-analyses support the association between mood disorders and obesity as both frequently co-occur in all races of populations examined. It is now well-established through longitudinal studies that obesity is a risk factor for mood disorders and vice versa. In the current review, we aim to address the evidence regarding 4 questions: (1) does obesity moderate response to antidepressants among patients with depressive disorders?, (2) does the presence of depressive disorders moderate the progression or outcome of obesity?, (3) does treatment of obesity moderate outcomes among patients with depressive disorders?, and (4) does treatment of depressive disorders moderate outcomes of obesity? In order to improve the interpretability of the results we confined the evaluations to studies where patients met the criteria for depressive disorders or obesity (i.e. BMI > 30). Extant evidence supports the association between obesity and adverse health outcomes among individuals with depressive disorders. In addition, the treatment of one condition (i.e. obesity or depressive disorders) appears to improve the course of the other condition. It might be beneficial to check for the other condition in patients presenting with one condition and treatment should be administered to treat both conditions. (C) 2016 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Clinical Neurology

Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine

Roger S. Mcintyre, Leslie Citrome, Hannah Cummings, Mark S. Todtenkopf, Laura A. Tan, Marni White, Sarah Akerman

Summary: The endogenous opioid system plays an important role in weight and metabolism regulation. Targeting this system may help mitigate antipsychotic-induced weight gain and metabolic dysregulation.

CNS SPECTRUMS (2023)

Review Clinical Neurology

Early optimized pharmacological treatment in patients with depression and chronic pain

Oloruntoba J. Oluboka, Martin A. Katzman, Jeffrey Habert, Atul Khullar, Margaret A. Oakander, Diane McIntosh, Roger S. McIntyre, Claudio N. Soares, Raymond W. Lam, Larry J. Klassen, Robert Tanguay

Summary: Major depressive disorder (MDD) is the leading cause of disability worldwide, and comorbid chronic pain exacerbates disability and healthcare burden. Managing patients with both MDD and chronic pain can be challenging due to shared underlying mechanisms. Current treatment guidelines address comorbid conditions such as anxiety and cardiovascular disease, but not chronic pain. Rapidly and aggressively treating depression according to guideline recommendations, using antidepressants with analgesic properties, while also addressing pain, is recommended based on clinical experience.

CNS SPECTRUMS (2023)

Article Clinical Neurology

The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia

Roger S. McIntyre, David G. Daniel, Eduard Vieta, Istvan Laszlovszky, Pascal J. Goetghebeur, Willie R. Earley, Mehul D. Patel

Summary: Post hoc analyses suggest that cariprazine may have potential benefits in improving cognitive symptoms in patients with bipolar I disorder and schizophrenia.

CNS SPECTRUMS (2023)

Review Psychiatry

Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder

Smadar V. Tourjman, Gabriella Buck, Didier Jutras-Aswad, Atul Khullar, Shane McInerney, Gayatri Saraf, Jairo V. Pinto, Stephane Potvin, Marie-Josee Poulin, Benicio N. Frey, Sidney H. Kennedy, Raymond W. Lam, Glenda MacQueen, Roumen Milev, Sagar V. Parikh, Arun Ravindran, Roger S. McIntyre, Ayal Schaffer, Valerie H. Taylor, Michael van Ameringen, Lakshmi N. Yatham, Serge Beaulieu

Summary: This task force report examines the association between cannabis use and bipolar disorder, major depressive disorder, and comorbid cannabis use disorder. The results indicate that cannabis use is associated with worsened course and functioning of both mood disorders, particularly in bipolar disorder. However, the treatment of comorbid cannabis use disorder and major depressive disorder did not show significant results.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2023)

Review Psychiatry

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder

Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, Roger S. McIntyre, Rodrigo B. Mansur, David Castle, Hilary Offman, Sagar Parikh, Benicio N. Frey, Ayal Schaffer, Kyle T. Greenwaym, Nicolas Garel, Serge Beaulieu, Sidney H. Kennedy, Raymond W. Lam, Roumen Milev, Arun Ravindran, Valerie Tourjman, Michael Van Ameringen, Lakshmi N. Yatham, Valerie Taylor

Summary: There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2023)

Article Clinical Neurology

Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement

William S. H. Kim, Mikaela K. Dimick, Danielle Omrin, Rachel H. B. Mitchell, Daniel Riegert, Anthony Levitt, Ayal Schaffer, Susan Belo, John Iazzetta, Garfield Detzler, Mabel Choi, Stephen Choi, Nathan Herrmann, Roger S. McIntyre, Bradley J. MacIntosh, Beverley A. Orser, Benjamin I. Goldstein

Summary: A study found that an anesthetic gas containing nitrous oxide can significantly reduce depression severity in patients with bipolar disorder. Patients who used nitrous oxide had greater reductions in depression severity on the same day compared to the placebo group. Baseline cerebral blood flow predicted the decrease in depression severity with nitrous oxide, but not with midazolam. The findings suggest differential associations of nitrous oxide versus midazolam with bipolar depression severity and cerebral hemodynamics.

BIPOLAR DISORDERS (2023)

Article Clinical Neurology

Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression

Farhan Fancy, Nelson B. Rodrigues, Joshua D. Di Vincenzo, Edmond H. Chau, Rickinder Sethi, Muhammad I. Husain, Hartej Gill, Aniqa Tabassum, Andrea Mckenzie, Lee Phan, Roger S. McIntyre, Joshua D. Rosenblat

Summary: This study observed the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. Results showed that ketamine significantly reduced depressive symptoms, suicidal thoughts, and anxiety, while improving functioning. The more infusions received, the more significant the reduction in symptoms.

BIPOLAR DISORDERS (2023)

Article Clinical Neurology

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression

Giovanni Martinotti, Bernardo Dell'Osso, Giorgio Di Lorenzo, Giuseppe Maina, Alessandro Bertolino, Massimo Clerici, Stefano Barlati, Gianluca Rosso, Marco Di Nicola, Matteo Marcatili, Giacomo d'Andrea, Clara Cavallotto, Stefania Chiappini, Sergio De Filippis, Giuseppe Nicolo, Pasquale De Fazio, Ileana Andriola, Raffaella Zanardi, Domenica Nucifora, Stefania Di Mauro, Roberta Bassetti, Mauro Pettorruso, Roger S. McIntyre, Stefano L. Sensi, Massimo di Giannantonio, Antonio Vita

Summary: This study aimed to compare the efficacy of esketamine in treating unipolar and bipolar treatment-resistant depression (TRD) and provide preliminary evidence of its effectiveness in bipolar TRD (B-TRD). The results showed that esketamine significantly reduced depressive symptoms in B-TRD patients compared to TRD patients, and it had a better anxiolytic action in B-TRD patients. The low risk of side effects confirmed the safety of this treatment.

BIPOLAR DISORDERS (2023)

Article Psychiatry

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents

Christoph U. Correll, Marco Solmi, Samuele Cortese, Maurizio Fava, Mikkel Hojlund, Helena C. Kraemer, Roger S. McIntyre, Daniel S. Pine, Lon S. Schneider, John M. Kane

Summary: Despite progress in pharmacotherapy, many mental disorders remain insufficiently treated due to limited knowledge of pathophysiology, lack of biological markers, and challenges in drug development and testing. This paper discusses promising drugs and innovative mechanisms of action undergoing testing for various psychiatric disorders, as well as the clinical trial parameters that need to be considered for successful drug development. It also highlights the hurdles and perils in new drug development and testing and emphasizes the importance of considering these factors for increased chances of success.

WORLD PSYCHIATRY (2023)

Article Environmental Sciences

Presence of Depression Is Associated with Functional Impairment in Middle-Aged and Elderly Chinese Adults with Vascular Disease/Diabetes Mellitus-A Cross-Sectional Study

Yuxiao Zhao, Yueying Zhang, Kayla M. Teopiz, Leanna M. W. Lui, Roger S. McIntyre, Bing Cao

Summary: This study investigated the association between depression, vascular diseases (hypertension, myocardial infarction, stroke), diabetes mellitus, and functional impairment in middle-aged and elderly Chinese people. The results showed that depression was associated with functional decline in individuals with vascular disease/diabetes mellitus, highlighting the importance of treating depression in addition to managing vascular diseases.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2023)

Article Clinical Neurology

Mediating role of personality traits in the association between multi-dimensional adverse childhood experiences and depressive symptoms among older adults: A 9-year prospective cohort study

Yanzhi Li, Lu Cheng, Lan Guo, Liwan Zhu, Hao Zhao, Caiyun Zhang, Manjun Shen, Yifeng Liu, Muhammad Youshay Jawad, Lingjiang Li, Wanxin Wang, Ciyong Lu, Roger S. McIntyre

Summary: This study explores the mediating role of personality traits in the relationship between adverse childhood experiences (ACEs) and depressive symptoms in older adults. The results suggest that maltreatment and household dysfunction induce depressive symptoms by increasing neuroticism, while poor parent-child bonding induces depressive symptoms by increasing neuroticism and reducing conscientiousness and extraversion.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Article Psychiatry

Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR)

Michael E. Thase, Zahinoor Ismail, Stine R. Meehan, Catherine Weiss, Stephane Alexandre Regnier, Klaus Groes Larsen, Roger S. McIntyre

Summary: In this study, a subset of 10 items from the IDS-SR was identified that can measure life engagement in MDD. Different approaches, including expert selection, patient interviews, and PCA, consistently identified these items. These findings suggest the potential for creating an IDS-SR life engagement subscale.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Review Neurosciences

The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review

Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni, Ziji Guo, Joshua D. Di Vincenzo, Giacomo d'Andrea, Aniqa Tabassum, Andrea Mckenzie, Sebastian Badulescu, Iria Grande, Roger S. McIntyre

Summary: The scoping review synthesized the current literature on the use of ketamine in bipolar depression. The preliminary evidence suggests that ketamine is a promising treatment with minimal risk and some effectiveness. Future studies should focus on ketamine's role in acute and maintenance treatment phases, as well as its effects on recurrence prevention and anti-suicidal measures.

BRAIN SCIENCES (2023)

Article Neurosciences

THINC-Integrated Tool (THINC-it): A Brief Measurement of Changes in Cognitive Functioning and Its Correlation with the Life Quality of Patients with Schizophrenia and Related Disorders-A Pilot Study

Joanna K. Szmyd, Karol Lewczuk, Kayla M. Teopiz, Roger S. McIntyre, Adam Wichniak

Summary: This pilot study assessed patients' cognitive functioning with the Polish version of the THINC-it tool and analyzed its association with self-reported quality of life. The results suggest that the THINC-it tool has utility as a cognitive measure in adults with schizophrenia in both clinical and research settings.

BRAIN SCIENCES (2023)

Article Psychiatry

Differential associations of mentally-active and passive sedentary behaviours and physical activity with putative cognitive decline in healthy individuals and those with bipolar disorder: Findings from the UK Biobank cohort

Elysha Ringin, David W. Dunstan, Roger S. McIntyre, Neville Owen, Michael Berk, Susan L. Rossell, Mats Hallgren, Tamsyn E. Van Rheenen

Summary: This study examined the impact of physical activity and sedentary behavior on cognitive function in individuals with bipolar disorder. The results showed a negative association between physical activity and passive sedentary behavior with cognitive function, and a positive association between mentally-active sedentary behavior and cognitive function. These associations were stronger in individuals with bipolar disorder.

MENTAL HEALTH AND PHYSICAL ACTIVITY (2023)

No Data Available